GW-0742

GW-0742 is a drug that acts as a selective agonist of peroxisome proliferator-activated receptor delta (PPARδ), and has been investigated for its potential to treat cardiovascular disease, diabetes, and metabolic syndrome. It is a member of the class of drugs known as PPAR modulators.

Pharmacology

GW-0742 is a potent and highly selective PPARδ agonist, with a Ki of 1 nM for human PPARδ and >1000-fold selectivity over PPARα and PPARγ. It is orally active and has been shown to have anti-inflammatory and anti-fibrotic activity, as well as the ability to improve insulin sensitivity in animal studies.

Clinical Trials

GW-0742 has been investigated in clinical trials for its potential to treat various conditions. In a study on patients with type 2 diabetes, it was found to improve insulin sensitivity and reduce blood glucose levels. In another study on patients with metabolic syndrome, it was found to reduce triglyceride levels and increase HDL cholesterol levels.

Potential Therapeutic Uses

Due to its anti-inflammatory and anti-fibrotic activity, GW-0742 has potential therapeutic uses in the treatment of a variety of conditions. These include cardiovascular disease, diabetes, metabolic syndrome, and potentially other conditions associated with inflammation and fibrosis.

Side Effects

As with all drugs, GW-0742 has the potential to cause side effects. These may include nausea, vomiting, diarrhea, and abdominal pain. However, these side effects are generally mild and manageable.

See Also

• Peroxisome proliferator-activated receptor
• PPAR modulator
• Cardiovascular disease
• Diabetes
• Metabolic syndrome

GW-0742 Resources
Latest articles Most recent articles Ongoing trials	Wikipedia